MP30-20 LOWER URINARY TRACT SYMPTOMS IN TRANSGENDER PERSONS TREATED WITH ESTROGENS

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Female Incontinence: Therapy I (MP30)1 Apr 2020MP30-20 LOWER URINARY TRACT SYMPTOMS IN TRANSGENDER PERSONS TREATED WITH ESTROGENS Al Ray*, Austin Fernstrum, Amr Mahran, Britt Conroy, David Sheyn, and Juan P. del Rincon Al Ray*Al Ray* More articles by this author , Austin FernstrumAustin Fernstrum More articles by this author , Amr MahranAmr Mahran More articles by this author , Britt ConroyBritt Conroy More articles by this author , David SheynDavid Sheyn More articles by this author , and Juan P. del RinconJuan P. del Rincon More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000869.020AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Lower urinary tract symptoms (LUTS) are common in the general population. Estradiol may play a role in LUTS. We used several survey instruments to analyze LUTS in male-to-female transgender subjects treated with estradiol. METHODS: Transgender male-to-female subjects treated with estradiol for at least 12 months were recruited from a single public health care system. A survey was designed to evaluate the prevalence of LUTS and thier affect on quality of life (QOL) in transgender subjects on sex hormone therapy. Patients with prior urethral or prostate surgery, or current UTI were excluded from the study. LUTS were assessed using the International Prostate Symptom Score (IPSS), the International Consultation on Incontinence Questionnaire (ICIQ). The WHOQOL-BREF instrument was used to investigate QOL, and the CED 8 instrument was used to screen for depression. Urinary incontinence was defined as reporting any amount of leakage on the ICIQ. The student T-test and the chi-square test were used for quantitative and categorical data analysis, respectively. RESULTS: A total of 129 subjects were prospectively recruited. Patients were stratified into 3 groups (mild, moderate, or severe symptoms) based on their IPSS. Group distribution was as follows: mild (n=11, 8.5 %), moderate (n=105, 8.14 %), and severe (n=13, 10.1 %). There were no significant differences according to age, race, BMI, alcohol consumption, and smoking status. Presence of urine leakage (per ICIQ) correlated with severity according to IPSS [9.1% in “mild” group vs. 54.3% in “moderate” group vs. 100% in “severe” group, p=<0.001]. Variables including urine incontinence before toileting (0% vs. 14.3% vs. 30.8), cough/sneeze (0% vs. 4.8% vs. 7.7%) and spotting (9.1% vs. 30.5% vs. 61.5%), correlated with IPSS severity group . The ICIQ score was also correlated with group by IPSS [0 in “mild” group vs. 3 in “moderate” group vs. 7 in “severe” group, p=<0.001]. CONCLUSIONS: We found a high prevalence of LUTS in this cohort of male-to-female transgender subjects. Urinary incontinence was positively correlated with worsening IPSS score in this cohort. Further investigation with longitudinal follow-up of a larger cohort is granted to better delineate the role of sex hormones and other factor on LUTS. Source of Funding: National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) grant 5K12DK100014 © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e446-e446 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Al Ray* More articles by this author Austin Fernstrum More articles by this author Amr Mahran More articles by this author Britt Conroy More articles by this author David Sheyn More articles by this author Juan P. del Rincon More articles by this author Expand All Advertisement PDF downloadLoading ...